This morning Atlas Venture and New Enterprise Associates announced that they have committed $29.4 million to launch Synlogic, a new Cambridge, MA-based upstart initially seeded last fall that has set out to build a platform that can create therapeutic microbes.
Startup GeneCentric Diagnostics pulled in $5 million in new Series A financing, according to reports from The Herald-Sun and Dow Jones VentureWire, among other media organizations. The money will help the North Carolina startup advance further development of gene-based diagnostic products designed to enable personalized treatments.
A three-year-old Pennsylvania startup pulled in the first tranche of a $11.6 million financing designed to help bring its first needle-based, minimally invasive diagnostic tool through regulatory clearance and commercial launch.
Startup SynapDx will team with the famed Broad Institute of Harvard and MIT to advance next-generation DNA sequencing for more accurate and clinically useful autism diagnostic tools.
Cambridge, MA's Sage Therapeutics has hauled in a $38 million Series C, convincing a who's-who of biotech investors to pitch in as it pushes forward with a portfolio of central nervous system treatments.
The antibody upstart Igenica has rounded up $14 million in venture cash to move its lead drug into the clinic. The Column Group, 5AM Ventures, OrbiMed and Third Rock Ventures all participated in the round.
Amazon founder and new media mogul Jeff Bezos is investing a bit of his personal fortune in Seattle-based Juno Therapeutics, a biotech startup that's been making some big waves in the immunotherapy world.
Foundation Medicine is touting some promising new data highlighting the utility of its signature diagnostic technology for blood cancers, news that will help the newly public Massachusetts startup maintain development and commercial momentum.
A pair of scientifists with deep roots in the Alzheimer's field is partnering up with two high-profile antibody development experts with a well-developed platform technology to launch a new biotech with ambitious plans to build a pipeline of new medications to combat the memory-wasting disease. And they're getting $10 million in seed cash from two marquee venture groups to get everything going.
A group of gene therapy experts with a pivotal-stage therapy that's already posted promising early-stage data is being spun out of The Children's Hospital of Philadelphia. The startup biotech is launching with a $50 million funding commitment.